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The definition of a counterfeit drug would at firsthand 
seem relatively simple: “a medicinal product that is 
produced and sold to deceptively represent its origin, 
authenticity or effectiveness”.1 However, when we 
actually consider the differences in terminology used 
among international providers of health care, it would 
seem that a legal definition of counterfeit as described 
in a legal text such as Black’s Law Dictionary remains 
inadequate. The escalation of “Pharma Fraud” has 
reached globally staggering levels, and is presently 
estimated to be about US$200 billion per year. It is 
therefore important that a universal definition of drug 
counterfeiting be developed; only then can we even 
start to police counterfeit drugs.2 Consequently, the 
World Health Organization has attempted to redefine 
a counterfeit drug and now specifically includes 
the concepts of correct and incorrect ingredients, 
insufficient or no active ingredients, and also fake 
packaging and mislabelling. It may be applied to both 
branded and generic products, and it is with this 
definition that most leading health care providers 
have reached a consensus.3 
 Hong Kong, as with many other first-world 
economies, has been distinctly proactive in the 
governance of counterfeit goods which also includes 
medicines in an attempt to limit both the economic 
and ultimate clinical harm of such products. But 
the additional problem with counterfeit medicinal 
products is the consequences they may have on 
general public health. Not only are these products 
fraudulent, they may cause significant harm, and 
therefore although legislation is imperative from 
an economic basis, it is also vitally important from 
a public health perspective. It is from a health care 
perspective that anti-counterfeit legislation should 
and is ultimately driven. 
 No one will ever really know the global level 
of medication counterfeiting, but it is estimated 
conservatively to be between 10 and 15% of all 
drugs, with some such as diazepam, codeine, and 
anabolic steroids being primarily of Chinese and 
Indian origin.4,5 Specifically data such as those from 
Taiwan’s Criminal Investigation Bureau showed that 
approximately US$9 million of counterfeit drugs had 
been seized in Taipei in 2006 and that their primary 
source was China.6 The huge influx of counterfeit 
drugs from China and India places Hong Kong, 
Singapore, and other developed economies in the 
South-East Asia region in a particularly vulnerable 
position, as they continue to exert and maintain 
exacting levels/standards of public health care and 
consumer protection. 
 The publication herein by Lai and Chan7 is 
timely in helping to demonstrate estimated levels 
of drug counterfeiting, continuing escalation of this 
problem, as well as the ordinances and civil cases 
enforced in Hong Kong to counter infiltration of these 
products into the region. What this paper serves to 
suggest is that the penalty for drug counterfeiting 
in the Hong Kong Special Administrative Region 
is perceived to be light and very few cases result 
in criminal prosecution. Although Hong Kong 
Ordinances serve to protect the public against drug 
counterfeiting exist, they are primarily Trade Marks, 
Patents, Trade Descriptions, and Pharmacy and 
Poisons Ordinances. As such, they do not address 
the issue uniquely and are possibly inadequate in 
dealing with this issue. 
 Neighbouring countries such as Singapore, 
Taiwan, and Vietnam have all introduced their 
respective Health Products and Pharmaceutical 
Products Acts, with significant penalties levied against 
perpetrators of counterfeiting medicinal products.8 
It is hoped that Hong Kong will follow suit and 
ultimately introduce its own specific anti-counterfeit 
drug law with subsequent legal enforcement of 
the respective Ordinance. Similarly, measures 
such as the serialisation of medicinal products, 
pharmacovigilance, and the education of lawyers and 
judges in counterfeit drug issues are all reasonable 
suggestions by Lai and Chan7 and would serve to 
improve public safety in this environment. Presently, 
the legal consequences for the counterfeiter appear 
to be minimal, whereas the adverse consequences 
for the patient are potentially serious. Thus, ensuring 
that patients have access to safe and quality assured 
medicines is surely an important clinical step and the 
mark of a moral society. 
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